Company profile RNA

Avidity Biosciences Inc
avidity biosciences is pioneering a new class of precision medicines – antibody-sirna conjugates (asc™) – to deliver nucleic acid therapeutics against genetic drivers of disease. our ascs have drug-like properties similar to antibodies and antibody-drug conjugates. importantly, their unique sirna-based “payloads” permit selective targeting of disease-associated mrnas ...against virtually any target of interest. our leadership includes seasoned scientists and executives with deep expertise in the fields of antibody conjugation, chemistry, formulations, oligonucleotide therapeutics, drug delivery and cancer biology. our employees are high energy, creative people who are passionate about solving hard problems and bringing new drugs to patients. we strive to work with partners to discover best-in-class molecules with the goal of long-term, joint value creation. we have also attracted support from top-tier investors including f-prime capital, ecor1 capital, brace pharma and other sophisticated Show More
Quarter analysis & expected interest

There is not enough data for Avidity Biosciences -stock -company to provide analysis

Correlation between past revenue and Avidity Biosciences -stock -company search interest

There is not enough data for Avidity Biosciences -stock -company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Avidity Biosciences -stock -company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Avidity Biosciences login to provide analysis

Correlation between past revenue and Avidity Biosciences login search interest

There is not enough data for Avidity Biosciences login to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Avidity Biosciences login to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Avidity Biosciences therapies to provide analysis

Correlation between past revenue and Avidity Biosciences therapies search interest

There is not enough data for Avidity Biosciences therapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Avidity Biosciences therapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for AOC 1001 clinical trial to provide analysis

Correlation between past revenue and AOC 1001 clinical trial search interest

There is not enough data for AOC 1001 clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for AOC 1001 clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for AOC 1044 clinical trial to provide analysis

Correlation between past revenue and AOC 1044 clinical trial search interest

There is not enough data for AOC 1044 clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for AOC 1044 clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for AOC 1020 clinical trial to provide analysis

Correlation between past revenue and AOC 1020 clinical trial search interest

There is not enough data for AOC 1020 clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for AOC 1020 clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for antibody oligonucleotide conjugates to provide analysis

Correlation between past revenue and antibody oligonucleotide conjugates search interest

There is not enough data for antibody oligonucleotide conjugates to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for antibody oligonucleotide conjugates to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for oligonucleotide-based therapies to provide analysis

Correlation between past revenue and oligonucleotide-based therapies search interest

There is not enough data for oligonucleotide-based therapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for oligonucleotide-based therapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for RNA
Earnings date: 2024-02-27 After close
Company name: Avidity Biosciences Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T16:40:00-04:00

PR Newswire
Atrium Therapeutics Reports First Quarter 2026 Financial Results

2026-05-01T11:11:01Z

Analyst Upgrades
HC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics

2026-04-23T08:00:00-04:00

PR Newswire
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

2026-04-20T22:46:00-04:00

PR Newswire
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-03-11T13:31:48Z

Analyst Upgrades
Wells Fargo Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

2026-02-27T09:19:00-05:00

PR Newswire
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

2026-02-26T16:02:00-05:00

PR Newswire
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

2026-02-23T08:00:00-05:00

PR Newswire
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

2026-02-18T17:00:00-05:00

PR Newswire
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

2026-02-02T21:44:00-05:00

PR Newswire
Avidity Biosciences Announces Expected Record Date for Spin-Off

2026-01-30T22:46:00-05:00

PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBHC, RNA, NEW, and TWO

2026-01-28T21:15:00Z

AccessWire
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

2025-12-01T18:59:00-05:00

PR Newswire
Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights

2025-12-01T15:20:00-05:00

PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN

2025-11-21T17:30:00-05:00

PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBX